List view / Grid view
20 September 2016 | By Drug Target Review
Drug Target Review talks to Joseph Zock, Senior Director of Product Management at IntelliCyt Corporation, to find out more about assay developments and future innovations in this area of drug discovery...
Researchers at Rush Medical Center are developing novel diagnostic tests to help guide treatment decisions for patients with non-small cell lung cancer...
20 September 2016 | By Vela Diagnostics
Fuelled by the rapid development of next-generation sequencing (NGS) technologies, it has become apparent that the technology is a key for the identification of genetic variants...
The discovery and development of novel drug candidates is a highly complex, time-consuming and expensive process. Pharmaceutical scientists and clinicians should, therefore, reevaluate and modify the existing standard platforms and increase their uptake of robust advanced technologies such as flow cytometry to overcome the bottlenecks in these processes...
Cholesterol is a ubiquitous molecule that, while essential for health, is probably best known as a risk factor for cardiovascular disease. It is also the obligate precursor for a wide range of metabolites, from steroid hormones to bile acids. Although studied for more than 100 years, recently there has been…
In vitro high-throughput cellular target-based assays are commonly used for hit identification targeting G-protein coupled receptors (GPCR). Agonist and antagonist identification of GPCRs often relies on the screening of large collections of chemicals using miniaturised in vitro cell-based functional assays. In the panel of assays, calcium mobilisation measured by aequorin…
Fibromyalgia (FM) has been described as a condition of heightened generalised sensitisation to sensory input presenting as a complex of symptoms dominated by chronic widespread pain characterised by hyperalgesia and allodynia. A range of co-morbidities of variable intensity, such as fatigue, sleep disturbance, cognitive impairment, anxiety and depression, are often…
As advances in protein engineering technology have led to the production of novel and more structurally complex biopharmaceuticals, the ability of these drugs to smoothly traverse the body and arrive at their intended target site has become more unpredictable...
Over the past few years several factors in the drug discovery industry have come together to drive an increased interest and subsequent surge in the use of high-content imaging. These include the high costs of attrition in the clinic due to lack of efficacy; increased hurdles and rising costs to…
Unforeseen efficacy and safety-related issues with drugs continue to be a major cause of their attrition, despite significant efforts that are expended to eliminate them prior to initiating clinical trials...
Starting in the 1970s, the drug discovery research process changed dramatically. Our understanding of biological targets and pathways grew and the largely empirical and target agnostic in vivo pharmacology approach was replaced with target-centric methods...
24 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Drug Target Review caught up with Dr Brian Murphy, CEO and Chief Medical Officer of Nemus Bioscience, to find out the latest in cannabinoid research…
15 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Drug Target Review caught up with Dr Emily Burns, Research Communications Manager Diabetes UK to find out how this smartphone craze could impact the rising levels of Diabetes…
22 July 2016 | By Victoria White, Digital Content Producer
Drug Target Review recently caught up with Lorence Kim, Chief Financial Officer of Moderna, to find out more about the company‘s collaboration with Vertex and using mRNA therapeutics to treat patients with cystic fibrosis...
20 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The NIH recently awarded $30 million to advance science towards a cure for HIV. Drug Target Review caught up with the Wistar Institute‘s Dr. Luis Montaner, co-leader of the BEAT-HIV project...
